Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations - Assets and liabilities reported as discontinued operations in balance sheet (Details)

v3.21.1
Discontinued Operations - Assets and liabilities reported as discontinued operations in balance sheet (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2021
Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Discontinued operations - current assets   $ 128 $ 181
Discontinued operations - current liabilities   1,893 1,960
U.S. commercialization activities | Discontinued operations      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Prepaid expenses and other current assets   128 181
Discontinued operations - current assets   128 181
Accounts payable   1,518 1,515
Accrued clinical trials expenses   9 80
Accrued sales allowances   57 61
Other accrued liabilities   309 304
Discontinued operations - current liabilities   $ 1,893 $ 1,960
Non-cash stock-based compensation expenses $ 24,000